Keywords
Ozempic
Diabetes Mellitus
Obesity
Biomedicine
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: The main objective of this study is to analyze the indiscriminate use of Semaglutide and the impacts that this practice may generate in the future. With the increasing use of this medication for non-prescription purposes, especially for weight loss, it is essential to understand the clinical, social and economic consequences of this trend. Literature review: This study was a narrative review of the off-label use of semaglutide (Ozempic®) for aesthetic purposes, highlighting its clinical and social risks. Although approved for the treatment of type 2 diabetes, its popularization on social media and self-medication have led to relevant adverse events, such as pancreatitis and gastrointestinal disorders. The review discussed the impact on the availability of the drug for diabetics and emphasized the importance of multidisciplinary management. Finally, it emphasized the essential role of biomedical professionals in promoting rational use, laboratory monitoring, and health education to reduce harm to public health. Final considerations: This review study analyzed the risks of indiscriminate use of semaglutide (Ozempic®), especially for aesthetic purposes and without medical advice. Despite its effectiveness in the treatment of type 2 diabetes and weight loss, uncontrolled use can cause serious adverse effects. The popularization of the drug on social media has favored self-medication. The work highlights the need for regulation, adequate information and more studies on the effects on non-diabetics.
References
ABDALQADIR NYAN, ADELI K. GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk. Microorganisms, 2022; 1(10): 2061.
AHRÉN B, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, Obesity and Metabolism, 2018; 20(9): 2210–2219.
AL-SAMIRY AH, et al. Proficiency and Knowledge of Community Pharmacists in the Use of Liraglutide and Semaglutide as Weight Reduction Agents. Al-Rafidain Journal of Medical Sciences, 2024; 6(1): 20–24.
ANDRIE EK. et al. Psychosocial Factors and Obesity in Adolescence: A Case-Control Study. Children (Basel, Switzerland), 2021; 8(4).
ANVISA. Canetas emagrecedoras só poderão ser vendidas com retenção da receita. 2025. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2025/canetas-emagrecedoras-so-poderao-ser-vendidas-com-retencao-de-receita. Acesso em: 9 jun. 2025.
BENDOTTIG, et al. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacological Research, 2022; 182: 106320.
BERNARDI F, et al. Comportamento de restrição alimentar e obesidade. Revista de Nutrição, 2005; 18(1): 85–93.
BEZERRATPW, et al. PERIGOS E CONSEQUÊNCIAS DO USO INDISCRIMINADO DE OZEMPIC NO EMAGRECIMENTO. REVISTA FOCO, 2024; 17(6): e5289.
CAMPBELLJE, DRUCKERDJ. Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metabolism, 2013; 17(6): 819–837.
CAMPOSAB, et al. Implicações do uso de Semaglutida no tratamento da obesidade: uma revisão sistemática. Brazilian Journal of Health Review, 2024; 7(5): e74150.
CASTROJV, et al. ANÁLOGOS DO GLP-1 E NEUROPROTEÇÃO: UMA REVISÃO SISTEMÁTICA. Brazilian Journal of Implantology and Health Sciences, 2023; 5(4): 2727–2740.
CONSELHO FEDERAL DE BIOMEDICINA. Habilitações. 2020. Disponível em: https://cfbm.gov.br/habilitacao. Acesso em: 20 maio. 2025.
CONSELHO REGIONAL DE BIOMEDICINA 4A REGIÃO. BIOMEDICINA: Saiba tudo sobre a profissão do futuro. 2022. Disponível em: http://portal.crbm4.org.br/index.php/11-noticias/147-biomedicina-saiba-tudo-sobre-a-profissao-do-futuro. Acesso em: 6 jun. 2025.
COSTAACC, et al. EFEITOS DA SEMAGLUTIDA NA PERDA DE GORDURA E DE MASSA MUSCULAR. Brazilian Journal of Implantology and Health Sciences, 2018; 6(2): 2018–2035.
CUNHA CLP. A Influência da Obesidade e da Atividade Física no Risco Cardiovascular. Arquivos Brasileiros de Cardiologia, 2022; 119(2): 244–245.
DAGHERC et al. Semaglutide-Induced Acute Pancreatitis Leading to Death After Four Years of Use. Cureus, 2024.
DAGHERC, et al. SEMAGLUTIDE-INDUCED ACUTE PANCREATITIS LEADING TO DEATH AFTER FOUR YEARS OF USE. Critical Care Medicine, 2025; 53(1).
DRUCKERDJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 2018; 27(4): 740–756.
DUFOURDR, et al. Diagnosis and Monitoring of Hepatic Injury. I. Performance Characteristics of Laboratory Tests. Clinical Chemistry, 2000; 46(12): 2027–2049.
GOMESHKBC, TREVISAN M. O uso do ozempic (semaglutida) como medicamento off label no tratamento da obesidade e como auxiliar na perda de peso. Revista Artigos. Com, 2021; 29: 1–7.
GUSMAO CALDEIRAG. OBESIDADE E OS DESAFIOS DO TRATAMENTO NUTRICIONAL. Revista Saúde Dos Vales, 2024; 5(1).
HÆDERSDALS. et al. The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. Mayo Clinic Proceedings, 2018; 93(2): 217–239.
HAN, SH et al. Practice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss. Aesthetic Surgery Journal, 2024; 44(4).
HINRICHSGR, et al. The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight. American Journal of Physiology-Cell Physiology, 2024; 326(2): C567–C572.
HOFFMANS, ADELI K. Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism. Medical Review, 2024; 4(4): 301–311.
LEEHEYDJ, et al. Acute Kidney Injury Associated With Semaglutide. Kidney Medicine, 2021; 3(2): 282–285.
LEXCHIN J, MINTZESB. Semaglutide: a new drug for the treatment of obesity. Drug and Therapeutics Bulletin, 2023; 61(12): 182–188.
LINHARES, FS, et al. Riscos potenciais relacionados ao uso indiscriminado da semaglutida. Revista JRG de Estudos Acadêmicos, 2024; 7(15): e151486.
LYRAR, et al. Manejo da terapia antidiabética no DM2. In: Diretriz da Sociedade Brasileira de Diabetes, 2024.
MACHADO S, et al. O USO DE ANÁLOGOS DE GLP-1 LIRAGLUTIDA, SEMAGLUTIDA E TIRZEPATIDA NO TRATAMENTO DA OBESIDADE: UMA REVISÃO DE LITERATURA. RECIMA21 - Revista Científica Multidisciplinar, 2023; 4(4): e442950.
MAHAPATRA MK, et al. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 2022; 23(3): 521–539.
MAHMOUDAM. An Overview of Epigenetics in Obesity: The Role of Lifestyle and Therapeutic Interventions. International journal of molecular sciences, 2022; 23(3).
MARSO SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2016; 375(4): 311–322.
MAYENDRARAJ A et al. GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation. Peptides, 2022; 151: 170749.
NAUCKMA, MEIER JJ. Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 2018; 20(S1): 5–21.
NOVOGRAD J et al. Semaglutide for Weight Loss: Was It Worth the Weight? Cardiology in Review, 2022; 30(6): 324–329.
PEREIRA LO, et al. Obesidade: hábitos nutricionais, sedentarismo e resistência à insulina. Arquivos Brasileiros de Endocrinologia & Metabologia, 2003; 47(2): 111–127.
PERKOVICV, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine, 2024; 391(2): 109–121.
PIMENTELDC, et al. Eficácia e segurança da semaglutida (OZEMPIC®) no tratamento da Obesidade: uma revisão bibliográfica. Cuadernos de Educación y Desarrollo, 2023; 15(11): 13875–13893.
PIRES WEBERT, et al. USO DO MEDICAMENTO SEMAGLUTIDA COMO ALIADO NO TRATAMENTO DA OBESIDADE. RECIMA21 - Revista Científica Multidisciplinar, 2023; 4(2): e422731.
POOROLAJALJ, et al. Behavioral factors influencing childhood obesity: a systematic review and meta-analysis. Obesity Research & Clinical Practice, 2020; 14(2): 109–118.
PORTOGI, et al. Impactos sistêmicos do uso off-label da semaglutida. Revista Eletrônica Acervo Científico, 2024; 47: e18999.
BHAGAVATHULA AS. Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface. BMC Global and Public Health, 2024; 2(1): 63.
RIBEIRO WR, BOGÉA EG. OS RISCOS E BENEFÍCIOS DO USO OFF-LABEL DA SEMAGLUTIDA (OZEMPIC) PARA EMAGRECIMENTO: UMA REVISÃO INTEGRATIVA. Revista ft, 2024; 29(140): 10–11.
RODRIGUESMB, et al. O uso off-label da semaglutida (Ozempic®) para emagrecimento e a atenção farmacêutica na dispensação. Brazilian Journal of Health Review, 2025; 8(1): e76780.
RYANN, SAVULESCUJ. The Ethics of Ozempic and Wegovy. Journal of Medical Ethics,2025;:jme-2024-110374.
SAGRATZKI RMG, et alO RISCO DE INTOXICAÇÃO PELO USO DO OZEMPIC (SEMAGLUTIDA) EM PACIENTES NÃO DIABÉTICOS. Brazilian Journal of Implantology and Health Sciences, 2023; 5(4): 1826–1837.
SASAKI LS, et al. Impacto do uso da semaglutida nos parâmetros cardiometabólicos de pacientes obesos não diabéticos: uma revisão sistemática. Cuadernos de Educación y Desarrollo, 2024; 16(13): e6745.
SHILLEH AH, et al.GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells. Peptides, 2024; 175: 171179.
SIJ, et al. The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders. Therapeutic Advances in Neurological Disorders, 2025; 18.
SILVA FMO, et al. Fatores ambientais associados à obesidade em população adulta de um município brasileiro de médio porte. Cadernos de Saúde Pública, 2019; 35(5).
SKOV J, et al. Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men. The Journal of Clinical Endocrinology & Metabolism, 2013; 98(4): E664–E671.
SOUZA MVS, et al. Eficácia e mecanismos de ação da Semaglutida no controle da obesidade. Journal of Medical and Biosciences Research, 2025; 2(1): 312–322.
TAKIZAWAY, et al. Effects of A GLP‑1 Receptor Agonist on Gastrointestinal Epithelial Cells. Scholars Academic Journal of Pharmacy, 2022; 11(4): 60–66.
TIRTHANIE, et al. Genetics and Obesity. [s.l: s.n.].
TRAPPS, BRIERLEYDI. Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment. British Journal of Pharmacology, 2022; 179(4): 557–570.
ULIANAAP, et al. Os efeitos da semaglutida na perda de peso e suas aplicações em publicações da base de dados do PubMed. REVISTA DELOS, 2024; 17(62): e3198.
WORLD HEALTH ORGANIZATION. Obesity and Overweight. 2025. Disponível em: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Acesso em: 9 jun. 2025.
YADAV HM, JAWAHAR A. Environmental Factors and Obesity. [s.l: s.n.].
ZANATTA MCA, et al. A Semaglutida aplicada ao tratamento da obesidade: perspectivas clínicas na literatura. Research, Society and Development, 2023; 12(9): e10012943295.
ZHANGY, et al. GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. Diabetes, 2019; 68(1): 34–44.
ZHENGZ, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 2024; 9(1): 234.